1085 related articles for article (PubMed ID: 33104267)
1. Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan.
Kubota-Koketsu R; Terada Y; Yunoki M; Sasaki T; Nakayama EE; Kamitani W; Shioda T
Transfusion; 2021 Feb; 61(2):356-360. PubMed ID: 33104267
[TBL] [Abstract][Full Text] [Related]
2. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray.
Camerini D; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Shandling A; Huynh V; Teng AA; Hermanson G; Pablo JV; Stumpf MM; Lester SN; Harcourt J; Tamin A; Rasheed M; Thornburg NJ; Satheshkumar PS; Liang X; Kennedy RB; Yee A; Townsend M; Campo JJ
Microbiol Spectr; 2021 Oct; 9(2):e0141621. PubMed ID: 34704808
[TBL] [Abstract][Full Text] [Related]
3. Human Milk Antibodies Against S1 and S2 Subunits from SARS-CoV-2, HCoV-OC43, and HCoV-229E in Mothers with A Confirmed COVID-19 PCR, Viral SYMPTOMS, and Unexposed Mothers.
Demers-Mathieu V; DaPra C; Mathijssen G; A Sela D; M Jarvinen K; Seppo A; Fels S; Medo E
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572480
[TBL] [Abstract][Full Text] [Related]
4. Antibody Mediated Immunity to SARS-CoV-2 and Human Coronaviruses: Multiplex Beads Assay and Volumetric Absorptive Microsampling to Generate Immune Repertoire Cartography.
Wang J; Li D; Zhou Q; Wiltse A; Zand MS
Front Immunol; 2021; 12():696370. PubMed ID: 34386006
[TBL] [Abstract][Full Text] [Related]
5. Coronavirus Pseudotypes for All Circulating Human Coronaviruses for Quantification of Cross-Neutralizing Antibody Responses.
Sampson AT; Heeney J; Cantoni D; Ferrari M; Sans MS; George C; Di Genova C; Mayora Neto M; Einhauser S; Asbach B; Wagner R; Baxendale H; Temperton N; Carnell G
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452443
[TBL] [Abstract][Full Text] [Related]
6. Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study.
Guo L; Wang Y; Kang L; Hu Y; Wang L; Zhong J; Chen H; Ren L; Gu X; Wang G; Wang C; Dong X; Wu C; Han L; Wang Y; Fan G; Zou X; Li H; Xu J; Jin Q; Cao B; Wang J
Emerg Microbes Infect; 2021 Dec; 10(1):664-676. PubMed ID: 33734013
[TBL] [Abstract][Full Text] [Related]
7. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Boosts Neutralizing Activity Against Seasonal Human Coronaviruses.
Lawrenz J; Xie Q; Zech F; Weil T; Seidel A; Krnavek D; van der Hoek L; Münch J; Müller JA; Kirchhoff F
Clin Infect Dis; 2022 Aug; 75(1):e653-e661. PubMed ID: 35079775
[TBL] [Abstract][Full Text] [Related]
8. Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post-COVID-19 Convalescent Samples.
Shrwani K; Sharma R; Krishnan M; Jones T; Mayora-Neto M; Cantoni D; Temperton NJ; Dobson SL; Subramaniam K; McNamara PS; Cunliffe NA; Turtle L; Zhang Q
J Infect Dis; 2021 Oct; 224(8):1305-1315. PubMed ID: 34161567
[TBL] [Abstract][Full Text] [Related]
9. Previous viral symptoms and individual mothers influenced the leveled duration of human milk antibodies cross-reactive to S1 and S2 subunits from SARS-CoV-2, HCoV-229E, and HCoV-OC43.
Demers-Mathieu V; DaPra C; Mathijssen GB; Medo E
J Perinatol; 2021 May; 41(5):952-960. PubMed ID: 33649442
[TBL] [Abstract][Full Text] [Related]
10. Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins.
Díez JM; Romero C; Vergara-Alert J; Belló-Perez M; Rodon J; Honrubia JM; Segalés J; Sola I; Enjuanes L; Gajardo R
Immunotherapy; 2020 Dec; 12(17):1247-1255. PubMed ID: 32900263
[No Abstract] [Full Text] [Related]
11. In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2.
Signer J; Jonsdottir HR; Albrich WC; Strasser M; Züst R; Ryter S; Ackermann-Gäumann R; Lenz N; Siegrist D; Suter A; Schoop R; Engler OB
Virol J; 2020 Sep; 17(1):136. PubMed ID: 32907596
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19.
Braun J; Loyal L; Frentsch M; Wendisch D; Georg P; Kurth F; Hippenstiel S; Dingeldey M; Kruse B; Fauchere F; Baysal E; Mangold M; Henze L; Lauster R; Mall MA; Beyer K; Röhmel J; Voigt S; Schmitz J; Miltenyi S; Demuth I; Müller MA; Hocke A; Witzenrath M; Suttorp N; Kern F; Reimer U; Wenschuh H; Drosten C; Corman VM; Giesecke-Thiel C; Sander LE; Thiel A
Nature; 2020 Nov; 587(7833):270-274. PubMed ID: 32726801
[TBL] [Abstract][Full Text] [Related]
13. Peptide microarray-based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development.
Holenya P; Lange PJ; Reimer U; Woltersdorf W; Panterodt T; Glas M; Wasner M; Eckey M; Drosch M; Hollidt JM; Naumann M; Kern F; Wenschuh H; Lange R; Schnatbaum K; Bier FF
Eur J Immunol; 2021 Jul; 51(7):1839-1849. PubMed ID: 33772767
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a multiplexed coronavirus antigen array for detection of SARS-CoV-2 specific IgG in COVID-19 convalescent plasma.
Huey L; Andersen G; Merkel PA; Morrison TE; McCarthy M; DomBourian MG; Annen K; Dawson ED; Rowlen KL; Knight V
J Immunol Methods; 2021 Oct; 497():113104. PubMed ID: 34303688
[TBL] [Abstract][Full Text] [Related]
15. Healthy donor T cell responses to common cold coronaviruses and SARS-CoV-2.
Woldemeskel BA; Kwaa AK; Garliss CC; Laeyendecker O; Ray SC; Blankson JN
J Clin Invest; 2020 Dec; 130(12):6631-6638. PubMed ID: 32966269
[TBL] [Abstract][Full Text] [Related]
16. An overview on the seven pathogenic human coronaviruses.
Kesheh MM; Hosseini P; Soltani S; Zandi M
Rev Med Virol; 2022 Mar; 32(2):e2282. PubMed ID: 34339073
[TBL] [Abstract][Full Text] [Related]
17. Seroprevalence and SARS-CoV-2 cross-reactivity of endemic coronavirus OC43 and 229E antibodies in Finnish children and adults.
Tamminen K; Salminen M; Blazevic V
Clin Immunol; 2021 Aug; 229():108782. PubMed ID: 34118402
[TBL] [Abstract][Full Text] [Related]
18. The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study.
Townsend JP; Hassler HB; Wang Z; Miura S; Singh J; Kumar S; Ruddle NH; Galvani AP; Dornburg A
Lancet Microbe; 2021 Dec; 2(12):e666-e675. PubMed ID: 34632431
[TBL] [Abstract][Full Text] [Related]
19. Diverse Humoral Immune Responses in Younger and Older Adult COVID-19 Patients.
Sasson JM; Campo JJ; Carpenter RM; Young MK; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Teng AA; Pablo JV; Liang X; Yee A; Petri WA; Camerini D
mBio; 2021 Jun; 12(3):e0122921. PubMed ID: 34182775
[TBL] [Abstract][Full Text] [Related]
20. Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications.
Dalakas MC; Bitzogli K; Alexopoulos H
Front Immunol; 2021; 12():627285. PubMed ID: 33679770
[No Abstract] [Full Text] [Related]
[Next] [New Search]
